QT IMAGING HOLDINGS, INC. Annual Report - How They Did This Year

I am breaking down QT Imaging’s performance to help you decide if this company fits your investment goals. Here is the plain-English guide to their recent filings.

1. What does this company do?

QT Imaging develops a specialized breast scanner. Traditional mammograms use radiation and uncomfortable compression. Their "QTscan" uses low-energy sound waves to create high-resolution 3D images. This technology works well for women with dense breast tissue, where standard mammograms often struggle. They want to disrupt the $3 billion breast imaging market with a non-invasive, radiation-free alternative.

2. Financial performance: The "Survival" Phase

To be blunt: the company is not yet profitable. In 2023, they lost about $18.6 million, up from a $14.2 million loss in 2022. Revenue is very low, totaling only $115,000 for the year from a few clinical installations. They burn through about $1.2 million in cash every month. While they have received $181 million in research grants from the NIH, that money is restricted to research and cannot fund daily business operations. Consequently, they rely on loans and selling more shares to keep the lights on.

3. Major wins and challenges

• Wins: The FDA cleared the QTscan for breast imaging, proving the technology is safe and effective. They also secured distribution deals in Japan and are working to enter the European market.
• Challenges: The company is in a "prove it" phase. They have sold fewer than 10 units worldwide. Their biggest hurdle is the "adoption gap"—convincing hospitals to replace or add to established, insurance-reimbursed equipment with a new system that currently lacks broad insurance coverage.

4. Financial health (The "Watch List")

This is vital for you as an investor. The company is in a high-risk position. By the end of 2023, they had a working capital deficit and an accumulated deficit of over $200 million. They have warned that there is "substantial doubt" about their ability to stay in business. Because they lack cash from operations, they frequently sell more shares and take on debt. This creates a cycle of issuing more shares, which reduces your ownership percentage and is very risky for long-term holders.

5. Key risks for your wallet

• Dilution: Because they rely on selling stock to raise money, the number of shares has grown significantly. Future exercises of warrants and notes will further reduce your ownership percentage.
• Management Experience: The leadership team is strong in research but currently lacks a track record in managing large-scale commercial sales or running a public company.
• Patent Expiration: Their business relies on over 40 patents. As these expire over the next 5–8 years, they must innovate quickly to prevent competitors from introducing cheaper, generic systems.
• Regulatory Hurdles: The FDA monitors them closely. Any failure to meet quality standards could lead to a suspension of their ability to sell the QTscan, which would effectively end their revenue potential.

6. Future outlook

The company is betting everything on their scanner becoming the new standard. Their current model assumes rapid sales growth and successful insurance negotiations. If these milestones are delayed by even 12–18 months, they will likely need to raise more cash, which would further hurt shareholder value.

Investor Takeaway: This is a high-risk, speculative investment. The company is currently in a "burn phase" where they spend significantly more than they earn. Before investing, ask yourself if you are comfortable with the high probability of further share dilution and the uncertainty regarding whether they can successfully transition from a research-focused entity to a profitable commercial business.